Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389714 | 0.89 | UGT2B7 (0.31) | — | |
| SCHEMBL31389572 | 0.73 | — | — | |
| SCHEMBL27671157 | 0.72 | ESR1 (0.33) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL23118976 | 0.72 | MEN1 (0.33) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL19083690 | 0.71 | ATM (0.36) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL26999754 | 0.69 | APLNR (0.34) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL27926042 | 0.69 | KMT2A (0.36) | ESR1MEN1KMT2AAPLNR | |
| SCHEMBL23897224 | 0.68 | TP53 (0.32) | ESR1MEN1KMT2A | |
| SCHEMBL14899050 | 0.68 | ESR1 (0.30) | ESR1MEN1KMT2A | |
| SCHEMBL19075667 | 0.67 | RIPK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | Prelude Therapeutis Incorporated (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| WO-2023056441-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023056441-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2022-10-13 | — | — | US | disclosed |
| CN-114786673-A | CDK inhibitors and their use as medicaments | 普莱鲁德疗法有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4028005-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050824-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673893-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
| US-20220324830-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
| US-12486277-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
| US-20230242543-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
| US-20210070761-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | CDK6, CDK3, CDK9 | ESR1 597/4885MEN1 2119/4885KMT2A 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.